BJDX
Bluejay Diagnostics, Inc.
Last earnings -3.7% on 2026-05-07
$1.14
▼ -20.83%$1.14▼ -82.41%
over 1Y
L $1.14H $14.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-20.8%
1W-65.6%
1M-73.7%
3M-41.5%
YTD-56.5%
1Y-82.4%
Avoid
Conviction
Horizon
Short (<3mo)
Street · 6 analysts
Sell
Cash-out clinical-stage shell: going-concern doubt, runway to Q3 2026, FDA filing not before 2027, and 1-for-32,000 of splits behind it.
Cash & equivalents $5.16M · FY2025
Bluejay is a pre-revenue, clinical-stage diagnostics company whose entire value rests on an unapproved product — the Symphony sepsis test — that management concedes will not even reach a 510(k) FDA submission until 2027 'at the earliest, if it is even able to generate sufficient clinical trial results to support such a submission.' There is no commercial business here: the only revenue in the dataset is $249K from FY2022, with FY2023–FY2025 revenue blank, against a FY2025 net loss of -$6.85M and operating cash burn of -$6.05M. The headline P/S of 4.5x is an artifact of stale 2022 revenue and is meaningless for a company that currently sells effectively nothing.
The filing itself is unambiguous about survival risk. Management states outright that these results 'raise substantial doubt with respect to its ability to continue as a going concern' and that cash resources — $5.16M at year-end 2025 against a burn of ~$6M/yr — are sufficient to fund operations only 'up to the third quarter of 2026.' That is roughly now. The 10-K spells out the downside if financing fails: delay or abandonment of trials, or Chapter 7 liquidation in which 'holders of shares of the Company's common stock could recoup little, if any, value.'
Is BJDX a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~30d expiry
- Long put 1 @ ~0.36 est
- Short put 1 @ ~0.36 est
debit $0max +$0max $0
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $249K | — | — | — |
| Gross profit | — | $48.9K | — | — | — |
| Operating income | -$3.23M | -$9.32M | -$10.3M | -$7.17M | -$6.95M |
| Net income | -$3.49M | -$9.30M | -$9.95M | -$7.72M | -$6.85M |
| Diluted EPS | -$0.41 | -$9.22 | -$3,631.48 | -$456.75 | -$15.25 |
| Net margin | — | -3733.1% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$3.99M
EV / EBITDA—
EV / Sales-16.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-580.6%
FCF yield-527.9%
Quality & risk
ROIC (est.)-91.9%
Free cash flow-$6.23M
Total debt—
Net cash$5.16M
Altman Z-Score-10.00 distress
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+75.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- S-3 Shelf registration (potential raise)2026-06-17
Filed S-3 shelf — registers future share sales, dilution overhang
- 8-K Officer / director change2026-06-09
Annual meeting vote results plus a board/officer change (Items 5.02/5.07)
- 8-K Material agreement2026-06-08
New financing agreement with unregistered share issuance — further dilution
- 8-K Material agreement2026-06-02
Entered a material agreement and issued a Reg FD update; terms undisclosed
- 8-K Earnings results2026-05-07
Q1 2026 10-Q: ongoing net loss, going-concern doubt, cash into Q3 2026
- 10-Q Quarterly report2026-05-07
Q1 2026 10-Q: ongoing net loss, going-concern doubt, cash into Q3 2026
- DEF 14A Proxy statement2026-04-30
Proxy for annual meeting — likely reverse-split/dilution authorization asks
- 8-K Reg FD disclosure2026-04-07
Reg FD investor/press update disclosed; no change to financials
- 8-K Material agreement2026-03-17
Financing with unregistered share sale — dilutive capital raise
Recent filings
all on EDGAR ↗EFFECTFiling2026-06-26open ↗424B3Filing2026-06-26open ↗S-3Filing2026-06-17open ↗8-KPeriod ending 2026-06-092026-06-09open ↗8-KPeriod ending 2026-06-022026-06-08open ↗SCHEDULE 13GFiling2026-06-05open ↗SCHEDULE 13D/AFiling2026-06-02open ↗SCHEDULE 13D/AFiling2026-06-02open ↗8-KPeriod ending 2026-05-272026-06-02open ↗4Period ending 2026-03-142026-05-18open ↗4Period ending 2026-03-142026-05-18open ↗4Period ending 2026-03-142026-05-18open ↗
Frequently asked
- Is Bluejay Diagnostics, Inc. (BJDX) a buy?
- BJDX currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Cash-out clinical-stage shell: going-concern doubt, runway to Q3 2026, FDA filing not before 2027, and 1-for-32,000 of splits behind it.
- What is Bluejay Diagnostics, Inc.'s quality score?
- BJDX scores 43.75/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001704287, latest 10-Q filed 2026-05-07) · EODHD · Proprietary analysis · as of 7/4/2026, 10:42:12 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:42 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.